Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at HC Wainwright

by · The Cerbat Gem

HC Wainwright reaffirmed their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH – Free Report) in a research note published on Monday morning, Benzinga reports. They currently have a $4.00 price objective on the stock.

Several other brokerages have also recently weighed in on HOTH. EF Hutton Acquisition Co. I raised Hoth Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 21st. Benchmark reiterated a “speculative buy” rating and set a $3.00 target price on shares of Hoth Therapeutics in a research note on Friday, October 11th.

Check Out Our Latest Stock Report on Hoth Therapeutics

Hoth Therapeutics Stock Down 1.8 %

NASDAQ HOTH opened at $0.88 on Monday. The firm’s 50-day simple moving average is $0.90 and its two-hundred day simple moving average is $0.94. Hoth Therapeutics has a 52 week low of $0.58 and a 52 week high of $1.73.

Hoth Therapeutics (NASDAQ:HOTH – Get Free Report) last released its earnings results on Friday, August 9th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.15. As a group, research analysts forecast that Hoth Therapeutics will post -1.18 EPS for the current fiscal year.

Hoth Therapeutics Company Profile

(Get Free Report)

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.

Featured Articles